The description more than 30 years ago of the role of de novo purine synthesis in T and B lymphocytes clonal proliferation opened the possibility for selective immunosuppression by targeting specifi c enzymatic pathways. Mycophenolic acid (MPA) blocks the key enzyme inosine monophosphate dehydrogenase and the production of guanosine nucleotides required for DNA synthesis. Two MPA formulations are currently used in clinical transplantation as part of the maintenance immunosuppressive regimen. Mycophenolate mofetil (MMF) was the fi rst MPA agent to be approved for the prevention of acute rejection following renal transplantation, in combination with cyclosporine and steroids. Enteric-coated mycophenolate sodium (EC-MPS) is an alternative MPA formulation available in clinical transplantation. In this review, we will discuss the clinical trials that have evaluated the effi cacy and safety of MPA in adult kidney transplantation for the prevention of acute rejection and their use in new combination regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy. We will also discuss MPA pharmacokinetics and the rationale for therapeutic drug monitoring in optimizing the balance between effi cacy and safety in individual patients.
Introduction
The outcome of solid organ transplantation during the past two decades has been tightly linked to the development of new immunosuppressive drug therapies. [1] [2] [3] [4] The advent of calcineurin inhibitors (CNI), cyclosporine (CsA) in the 1980s and tacrolimus (TAC) in the 1990s, together with anti-T-cell induction therapies resulted in a spectacular improvement of one-year allograft survival when compared to the previous combination of azathioprine and corticosteroids. [4] [5] [6] The primary focus of immunosuppressive protocols has always been the prevention of acute allograft rejection, a leading cause of graft loss during the fi rst year after transplantation and a risk factor for the development of chronic allograft dysfunction and poor long-term graft outcome. However, while the rates of acute rejection episodes and short-term patient and allograft survival have steadily improved under CNI-based immunosuppressive regimens, optimal long-term allograft survival remains a problem. [6] [7] [8] Indeed, despite potent anti-rejection therapies, there is still an inexorable loss of transplanted organs due to chronic allograft dysfunction, also referred to as chronic allograft nephropathy (CAN) in kidney transplantation, a process involving immunological factors and nonimmunological drug-related toxicity. 9, 10 Besides increased cardiovascular risk factors such as hypertension, hyperlipidemia and diabetes leading to increased patient morbidity and mortality, CNI have been associated with nephrotoxicity and vasculopathy, contributing to CAN. Thus, research efforts are now focused on fi nding effi cacious immunosuppressive drug regimens with less graft and patient toxicity.
In this paper, we review the effi cacy and safety of mycophenolic acid (MPA) formulations in human adult kidney transplantation. Based on the results of three major clinical trials, mycophenolate mofetil (MMF) was the fi rst MPA agent to be approved for the prevention of acute rejection following renal transplantation, in combination with CsA and steroids. The results of these initial trials including long-term follow-up data of the study population and subgroup analysis will be discussed, as triple therapy of CsA-MMF-prednisone has since become the standard maintenance immunosuppression in many renal transplantation centers. We will also review trials evaluating MMF in new combination regimens aiming at minimizing CNI toxicity and CAN, as well as the use of entericcoated mycophenolate sodium (EC-MPS), an alternative MPA formulation. Finally, because of the complex pharmacokinetics of MPA resulting in inter-and intra-patient variability in drug exposure, therapeutic drug monitoring (TDM) of MPA could provide further improvement in the clinical management of individual patients and optimal immunosuppression.
Cellular targets of MPA and pharmacology
T-cells play a central role in the immune response to an allograft and most current immunosuppressive drugs target T-cell activation and/or clonal expansion. Once T-cells have been specifi cally primed through their T-cell receptor (TCR) by alloantigens, the calcium-calcineurin pathway is activated, leading to the expression of survival and proinfl ammatory cytokines and their receptors. The engagement of the IL-2 receptor delivers growth and proliferation signals via the down-stream phophoinositide-3-kinase (PI3K) and the mammalian target-of-rapamycin (mTOR) pathways, initiating the cell cycle. Whereas CNI (CsA and TAC) inhibit the calcium-calcineurin pathway and alloantigen-dependent T-cell activation, MPA inhibits T-and B-cell proliferation ( Figure 1) .
The role of de novo purine synthesis in lymphocyte clonal proliferation was fi rst highlighted by the characterization of patients with inherited immunodefi ciency syndromes and the identifi cation of key enzymatic pathways. 11 MPA was originally obtained from a Penicillium fungus and shown to have anti-neoplastic, anti-viral, anti-fungal and immunosuppressive activities.
12-14 MPA selectively and reversibly blocks an important step in the de novo synthesis of purine by inhibiting inosine monophosphate (IMP) dehydrogenase, an enzyme that allows the conversion of IMP to xanthosine monophosphate, the precursor of guanosine nucleotides required for DNA synthesis ( Figure 1 ). 15 MPA has no effect on the other route of purine nucleotide synthesis, the salvage pathway, where guanine obtained from the breakdown of nucleic acids is directly converted into guanosine monophosphate. Unlike neutrophils, lymphocytes depend primarily on the de novo purine synthesis pathway and may be more specifi cally targeted by MPA. In addition, different isoforms of IMP dehydrogenase exist, and MPA has a higher binding affi nity for the type II isoform, which is upregulated in stimulated lymphocytes. Thus, MPA preferentially inhibits the division of activated lymphocytes, and, on theoretical grounds, would result in a better targeted immunosuppression with fewer side-effects that the less selective anti-metabolite azathioprine (AZA).
In vitro and in vivo studies have shown that MPA inhibits the generation of cytotoxic T cells and prevents antibody production by B cells, but has no direct effect on the production of cytokines. 16 The synthesis of glycoproteins such as leukocyte surface adhesion molecules (selectins and integrins) is dependant on guanosine nucleotides. MPA treatment may thus also interfere with the recruitment of lymphocytes to sites of infl ammation and their interaction with the endothelium of a vascularized allograft. 17 Mycophenolate mofetil (MMF, CellCept ® )
MMF, formerly called RS-61443, is an ester prodrug of MPA with better bioavailability (94%). After oral administration and absorption, the ester is rapidly cleaved, releasing the active MPA component with a maximum plasma concentration at 2 hours. MPA then undergoes hepatic glucuroconjugation to form an inactive glucuronide metabolite (MPAG) which is eliminated in the urine (90%) or excreted into the bile. In the gut, bacterial enzymes can convert this metabolite back to MPA, which is reabsorbed into circulation (enterohepatic recirculation), leading to a secondary plasma peak of MPA 6 to 12 hours after oral administration. 18 The mean elimination half-life of MPA is 8 to 16 hours.
Enteric-coated mycophenolate sodium (EC-MPS, Myfortic ® )
Because the use of MMF has been associated with a high incidence of gastrointestinal (GI) adverse events, a new MPA formulation was developed. EC-MPS lacks the mofetil ester and releases MPA only when the alkaline environment of the small intestine is reached. Dissolution studies with EC-MPS have shown that MPA is maximally released at pH 6.0 to 6.8. 19 Pharmacokinetic studies in renal transplant patients have demonstrated that EC-MPS 720 mg twice a day provides an MPA exposure bioequivalent to MMF 1 g twice a day and has a comparable safety profi le. 19, 20 A subsequent meta-analysis of pharmacokinetic data from three clinical trials (n = 82 patients) confi rmed the bioequivalence of EC-MPS and MMF for both MPA and metabolite exposure, and for maximum plasma MPA concentrations.
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Effi cacy of MMF in current immunosuppressive regimens after kidney transplantation Current established immunosuppressive strategies in kidney transplantation often include an induction agent (monoclonal or polyclonal anti-T-cell antibodies) based on the immunologic risk of the recipient, followed by a maintenance regimen combining a CNI and an anti-proliferative agent, with or without corticosteroids. [2] [3] [4] As MMF was the fi rst MPA formulation approved in clinical kidney transplantation, more extensive clinical data are available with this drug in comparison to EC-MPS.
MMF therapy for the prevention of acute allograft rejection in cyclosporine-based regimens
The primary objective for the addition of MMF to maintenance immunosuppression was to reduce the rate of acute rejection. Three large multicenter, prospective, randomized, double-blinded trials have evaluated MMF therapy for the prevention of acute allograft rejection in fi rst or second renal cadaveric transplantation: the European Mycophenolate Mofetil Cooperative Study, US Renal Transplant Mycophenolate Mofetil Study Group, and the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group which was performed in Europe, Canada and Australia. [22] [23] [24] Overall, these trials included 55 transplantation centers and were the largest immunosuppressive prospective randomized drug trials ever performed in transplantation. In the US and Tricontinental trials, MMF (2 g/day and 3 g/day) was compared to AZA, with concomitant treatment of CsA and corticosteroids in all the groups. Anti-thymocyte globulin was given in the US trial, while patients received no induction therapy in the Tricontinental trial. In the European trial, MMF (2 g/day and 3 g/day) was compared to a placebo. In this trial, all the groups were also under CsA-prednisone maintenance therapy, but none received induction therapy. The primary end-point for all three trials was treatment failure, defi ned as biopsy-proven acute rejection, graft loss, patient death or withdrawal from the study during the fi rst 6 months after transplantation. All three trials also reported drug related side-effects.
One-year effi cacy data from these three trials were evaluated in a pooled analysis. 25 Altogether, 1493 patients had been randomized, with 505, 490 and 498 patients in MMF 2 g/day, 3 g/day and AZA/placebo groups, respectively. The incidence of biopsy-proven acute rejection within the fi rst year was signifi cantly lower in transplant recipients treated with MMF (19.8% and 16.5% for MMF 2 g/day and 3 g/day, respectively) compared to patients receiving AZA or placebo (40.8%). In addition, the rejection episodes were less severe in the MMF groups as evaluated by Banff scores on biopsies (9.9%, 8.1% and 23.9% grade II or more severe histological scores in MMF 2 g/day, 3 g/day and AZA/placebo treatment groups, respectively) and the requirement for high-dose steroids and anti-lymphocyte antibodies. There was however no signifi cant difference in graft function (evaluated by mean serum creatinine), nor in graft and patient survival in the fi rst year, within the treatment groups. Of note, study withdrawal due to adverse events was more common in MMF groups (8.7%, 14.7% and 5.2% in MMF 2 g/day, 3 g/day and AZA/placebo treatment groups, respectively). GI toxicity (mainly diarrhea, esophagitis and gastritis) was more frequent under MMF compared to AZA therapy, but in most cases improved following a decrease in MMF dose and it did not result in study discontinuation. Opportunistic infections occurred in all treatment groups but tissue-invasive CMV was more common in the MMF treatment groups. There was no report of hepatotoxicity; neutropenia and thrombocytopenia were infrequent, while anemia was similarly observed in MMF and AZA treatment groups.
Three-year follow-up data have been published for the Tricontinental and European trials. 26, 27 In the Tricontinental study, overall graft survival and function remained comparable in all treatment groups. However, patients who had experienced biopsy-proven rejection within 6 months after transplantation were more likely (26.1% vs 5.7%) to lose their transplant at 3 years compared to patients free from early acute rejection, and, graft loss due to rejection was reduced in patients receiving MMF (5.8%, 3.0% and 9.9% in MMF 2 g/day, 3 g/day and AZA treatment groups, respectively). This illustrated the potential negative impact of early acute rejection episodes on long-term graft outcome as previously reported. 28 In the European study, treatment of recipients with MMF 2 g/day resulted in a signifi cant increase in graft survival at 3 years (84.8%, 81.2% in MMF 2 g/day and 3 g/day, respectively) compared to placebo (78%). In both studies, no new signifi cant adverse event occurred during the second and third year following transplantation. These later follow-up AZA/placebo-controlled studies have thus established the safety and effi cacy of MMF treatment in renal transplantation.
Since the introduction of MMF, the original oil-based formulation of CsA has been largely replaced by the microemulsion formula of cyclosporine in immunosuppressive regimens after renal transplantation. The effi cacy and tolerability of MMF in combination with CsA-microemulsion and prednisone was studied in fi rst-time recipients of cadaveric or living-donor renal transplants. 29 Treatment failure and the cumulative rate of acute rejection were signifi cantly lower in the MMF treatment group compared with the AZA treatment group (p = 0.007 and p = 0.03, respectively). Death and safety profi les were similar in both treatment groups over the12-months study period, indicating that MMF can be combined with CsA-microemulsion and prednisone for maintenance immunosuppression after renal transplantation.
MMF as therapy in acute allograft rejection
Following on these initial data, randomized trials have established the potential of MMF in the treatment of acute rejection episodes as an alternative and as an adjuvant therapy to high-dose corticosteroids [30] [31] [32] in renal transplant recipients treated primarily with CsA-prednisone maintenance immunosuppression. In combination with intravenous corticosteroids, MMF 3 g/day was significantly more effective than AZA and reduced the need for anti-lymphocyte antibodies (29.2% vs 51.9%). It was also shown that under MMF therapy, subsequent rejection episodes, graft loss or death were less likely compared to AZA (38.9% vs 65.7%) during the 3 years after transplantation. Renal function of the surviving grafts at 3 years was however similar in both treatment groups. 32 Besides reducing the incidence of early acute rejection episodes, immunosuppressive protocols combining CsA and MMF have been shown to reduce late allograft rejection, thus improving long-term patient and graft survival. Data analysis of 47693 primary renal allograft recipients, reported to the United States Renal Data System (USRDS) between 1988 and 1998, has shown that long-term continuous MMF therapy was associated with a 65% decreased risk of developing late acute rejection (beyond 1 year after transplantation) as compared to AZA (RR = 0.35, CI 0.27-0.45, p Ͻ 0.001). 33 In this study population the rate of acute rejection episodes in the AZA treatment group was 6.1% at 2 years and 9.3% at 3 years, vs 0.9% and 1.1% at 2 and 3 years after transplantation in the MMF group, respectively. 33 
MMF therapy in combination with tacrolimus
The initial usage of MMF in renal transplantation was in combination with CsA and steroids. With the advent of new immunosuppressive drugs, subsequent prospective randomized trials have evaluated MMF in combination regimens with these agents. Several studies have demonstrated the pharmacologic synergism between MMF and tacrolimus (TAC). 34 A few large multi-center randomized trials have evaluated the risk of acute rejection in adult cadaveric kidney-transplant recipients under a combination therapy of TAC-MMF-steroids compared to TAC-steroids, TAC-AZAsteroids or CsA-MMF-steroids. [35] [36] [37] [38] [39] TAC-MMF-steroids therapy was superior to TAC-steroids in preventing acute rejection (27% vs 44%). 35 In one study, TAC-AZAsteroids and TAC-MMF 1 g/day-steroids resulted in similar effi ciency in preventing acute rejection (35,6% vs 34.9% acute rejection episodes), while TAC-MMF 2 g/day-steroids appeared to provide greater protection (8.9%) but without significant improvement in graft or patient survival at 1 year. Furthermore, patients in the MMF 2 g/day treatment group had their total daily dosage often reduced due to GI or hematological side-effects, so that at 6 months the mean daily dose in this group was 1.5 g/day. 36 In another trial with 1-2-and 3-year follow-up, there was no signifi cant difference in the incidence of acute rejection, graft and patient survival between TAC-MMF-steroids, TAC-AZA-steroids and CsA-MMF-steroids treatment groups. [37] [38] [39] Median serum creatinine levels were higher in the CsA treatment group compared to the TAC-based regimens. Of note, among the subset of patients with delayed graft function, there was a signifi cant improvement in graft survival under the TAC-MMF combination therapy (84%, 70% and 61% for TAC-MMF-steroids, TAC-AZA-steroids and CsA-MMFsteroids, respectively). In summary, these studies have provided evidence that TAC-MMF-prednisone triple therapy was safe and equally effective than CsA-MMF-prednisone in preventing acute rejection in renal transplantation. Moreover the short-term results of the recent large prospective Effi cacy Limiting Toxicity Elimination (ELITE) -Symphony study in de novo renal transplantation, suggest that TAC-MMFprednisone maintenance immunosuppression may even be advantageous for graft function and survival, with lower acute rejection rates. 40 In this study 1645 kidney-transplant recipients were randomized in 4 treatment groups: standard-dose CsA-MMF-prednisone (CsA target trough levels 130-300 ng/mL for 3 months, then 100-200 ng/mL), or daclizumab induction with MMF-prednisone in combination with low-dose CsA (target trough levels 50-100 ng/mL), low-dose TAC (target trough levels 3-7 ng/mL), low-dose sirolimus (SRL, target trough levels 4-8 ng/mL). At 12 months after transplantation, a lower rate of biopsy-proven acute rejection occurred in patients receiving low-dose TAC (12.3%, 25.8%, 24%, 37.2% for low-dose TAC, standarddose CsA, low-dose CsA, or low-dose SRL treatment groups, respectively) and renal function was better preserved than in the other three groups (mean calculated GFR 65.4 mL/min vs range 56.7-59.4 mL/min, p Ͻ 0.001).
MMF in high-immunologic risk patients
The reported successes of CsA-MMF-prednisone maintenance immunosuppression in adult low-immunologic risk kidneytransplant recipients has led to the evaluation of MMF safety and effi cacy in high risk recipients such as in pediatric transplantation 41 as well as for adult African-Americans. 42, 43 In a post-hoc analysis of ethnic subgroups done in the US study, 24 the rate of biopsy-proven acute rejection was higher in any of the treatment groups among African-American compared to Caucasian recipients. African-Americans had more severe rejection episodes and higher serum creatinine levels at 6 months after transplantation, regardless of the treatment group, but data indicated that they had an additional benefi t from the 3 g vs 2 g/day MMF dose in association with CsA and steroids (47.5%, 31.8%, 12% incidence of acute rejection for AZA, MMF 2 g/day, MMF 3 g/day treatment groups, respectively). 42 
MMF in CNI-sparing immunosuppressive regimens
The addition of MMF to CNI-based maintenance immunosuppresssion has signifi cantly reduced the rates of acute rejection in the fi rst year after transplantation, however without a signifi cant impact in long-term (ie, Ͼ5 years) graft and patient outcome. CNI are a major cause of poor graft and patient survival more that 1 year after transplantation as they can contribute to CAN and are associated with increased cardiovascular risk factors. [7] [8] [9] [10] Reducing CNI dosage or avoiding CNI could therefore be an approach to improve long-term outcome in renal transplantation. 44 Thus, the introduction of potent anti-proliferative agents such as MMF in maintenance immunosuppressive regimens may allow CNI-minimization without increasing the immunological risk.
Golshayan et al
As CNI-MMF maintenance immunosuppression was shown to prevent long-term failure of kidney grafts, independent of its effect on early and late acute rejection episodes, 33, 45, 46 randomized multi-center prospective studies have further investigated the impact of MMF-based regimens after CNI minimization or withdrawal. The aims were either to avoid chronic nephrotoxicity in patients with stable kidney function, [47] [48] [49] [50] [51] [52] [53] or to improve/maintain kidney function in the presence of CAN (defi ned by declining renal function and/or characteristic histological changes on protocol biopsies). [54] [55] [56] [57] [58] [59] [60] [61] In the fi rst prospective clinical trials evaluating the safety of CsA-withdrawal strategies in renal transplantation, recipients with stable graft function on CsA-MMF-prednisone maintenance therapy over 1 year after transplantation were randomized to remain on CsA-MMF-prednisone standard therapy or MMF-prednisone treatment arm. 47, 48 Renal function as well as some cardiovascular risk factors such as serum cholesterol levels signifi cantly improved after CsA withdrawal. Acute rejection rates at 6 months (10.6% vs 2.4%) and 5 years (16% vs 1%) were signifi cantly higher in the CsA-withdrawal group versus controls, without however an impact on patient and graft survival rates at 5 years. 48 To preserve renal function without increasing the risk of immunologic injury, CNI-reduction strategies (50% dose-reduction) have been successfully reported. 49 Based on the encouraging results obtained with the switch (Ͼ1 year after transplantation) to low-dose CNI maintenance immunosuppression in recipients with stable renal function, multi-center prospective randomized studies investigated the effi cacy and safety of de novo (ie, at the time of transplantation) low-dose CNI-MMF-prednisone and MMF-prednisone (CNI-avoidance) immunosuppressive regimens in renal transplantation. To control the immunological risk in these settings, recipients either received induction therapies with anti-T-cells antibodies 40, 50, 51 and/or an additional anti-proliferative agent such as an mTOR-inhibitor. 52, [62] [63] [64] [65] In the CAESAR study, CsA-minimization under the cover of basiliximab did not result in signifi cant improvement of renal function and the incidence of biopsy-proven acute rejection was signifi cantly higher in the CsA-withdrawal group (38%) as compared to the low-dose CsA (25.4%) or standard dose CsA (27.5%) groups (p Ͻ 0.05). 50 Interestingly, in comparison, the basiliximab induction followed by low-dose TAC-MMF-prednisone immunosuppressive regimen used in the ELITE-Symphony study resulted in improved 1-year graft function with lower acute rejection rates. 40 Following extensive preclinical studies, a recent multi-center randomized phase II kidney transplantation clinical trial has investigated the effi cacy and safety of belatacept, a molecule that blocks T-cell activation and is not known to be nephrotoxic, as an alternative to CNI in maintenance immunosuppression. 53 One-year results showed similar acute rejection rates in both arms (19% vs 18% in belatacept-MMF-prednisone and CsA-MMF-prednisone groups, respectively), while in the belatacept treatment group renal function was signifi cantly improved with a lower prevalence of CAN on protocol biopsies.
CNI dose-reduction was also attempted under the cover of MMF-prednisone in recipients with declining renal function and CAN confi rmed on biopsies. [54] [55] [56] [57] [58] [59] [60] [61] In general, in these transplant recipients, serum creatinine levels stabilized or decreased after CNI-minimization and the switch from AZA-prednisone to MMF-prednisone maintenance immunosuppression, without an increase in the incidence of acute rejection. Thus, these observational and randomized clinical trials suggest that it could be a safe and effective therapeutic option in selected renal transplant recipients with worsening renal function. Furthermore, the reduction or complete withdrawal of CNI could also improve metabolic parameters and blood pressure control and decrease patient's cardiovascular morbidity.
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Safety and effi cacy of EC-MPS versus MMF
Side-effects associated with MMF
The majority of data concerning the safety and tolerability of MMF in transplant recipients were obtained from the three earliest prospective randomized double-blinded clinical trials in renal transplantation, evaluating MMF at 2 g/day and 3 g/day. [22] [23] [24] Long-term trials of patients with psoriasis treated with MMF are also available. 66 Overall, MMF was well tolerated with most of the symptoms being dose-dependant as the reported side-effects generally resolved with the reduction of the dose. In these studies, GI toxicity (mainly diarrhea, nausea, esophagitis and gastritis) and tissueinvasive CMV were more common with MMF therapy, while myelosuppression (mainly leucopenia and anemia, only rarely neutropenia) and other opportunistic infections also occurred in AZA treatment groups. GI side-effects can occur in up to 45% of patients treated with MMF and are in part due to systemic MPA exposure and its antiproliferative effect on enterocytes. [22] [23] [24] 67 Dose reductions or temporarily discontinuation of MMF may be suffi cient to relieve the symptoms but can result in sub-therapeutic levels.
EC-MPS is an alternative formulation of MPA, designed to reduce GI toxicity. In a few multi-center prospective open-label studies, MMF-treated kidney-transplant patients experiencing GI complaints were successfully converted to equimolar doses of EC-MPS. 68, 69 These studies have shown that following the switch to EC-MPS, GI-related symptoms and health-related quality of life, as assessed by self-administered patient questionnaires, improved signifi cantly 68 and this was a sustained effect over time after conversion to EC-MPS. 69 Bioequivalence, safety and tolerability of EC-MPS in renal transplantation
Randomized clinical trials in renal transplantation have evaluated MPA drug exposure and the bioequivalence of EC-MPS compared to MMF, as well as the therapeutic efficacy and safety of EC-MPS in renal transplantation, either de novo after transplantation as part of CNI-based maintenance immunosuppression or after a switch from MMF. [70] [71] [72] The ERL B301 Study group, an international, randomized, double-blind trial, has assessed the therapeutic equivalence of EC-MPS (720 mg bid) and MMF (1000 mg bid), with concomitant CsA microemulsion and corticosteroids, in 423 de novo kidney-transplant patients. 70, 71 At 12 months, the incidence of biopsy proven acute rejection, graft loss or death was 26.3% and 28.1% (biopsy proven acute rejection alone 22.5% and 24.3%) for EC-MPS and MMF, respectively. The safety profi le and interestingly the incidence of GI adverse events were similar for both groups. 70 In the extension study, after 1 year of treatment the patients fi rst randomized in the MMF group were converted to EC-MPS, and both groups were followed for 2 more years. 71 The overall incidence of adverse events, acute rejection and graft loss during the extension phase was comparable to that seen in the core study, and in the MMF arm of other similar controlled randomized studies. This study established the long-term effi cacy and tolerability of EC-MPS in association with CsA and steroids, as well as the safety of converting renal transplant patients from MMF to EC-MPS.
The myfortic Prospective Multicentre Study (myPROMS) was an international, prospective, open-label, clinical trial designed to assess the effi cacy and safety of EC-MPS in combination with CsA microemulsion in a large population of kidney-transplant recipients. [73] [74] [75] The study had a predefi ned core protocol with 14 sub-studies addressing different aspects related to EC-MPS treatment. All participants were treated with EC-MPS and CsA microemulsion (C2 level monitoring), with or without corticosteroids, and induction therapy was given as per center practice. The primary effi cacy evaluation was the rate of treatment failure, defi ned as biopsy-proven acute rejection, graft loss or death of the recipient during the fi rst 6 and 12 months after transplantation. Safety and tolerability analyses were also performed for all patients, including reported adverse-events, hematology and chemistry profi les, infections and malignancies. Data were pooled from multiple centers for planned analysis of sub-protocols.
In a 6-month sub-study (Asia, Europe, and Latin America), the effi cacy and safety of converting stable renal transplant recipients (n = 564) from MMF to a bioequivalent dose of EC-MPS were evaluated. 73 Patients who were at least at 3 months post transplantation (ie, maintenance patients) and had a stable graft function under CsA-MMF with or without corticosteroids therapy were eligible to enter the subprotocol. After switch from MMF to EC-MPS, renal function remained stable throughout the trial (baseline calculated creatinine clearance 65.3 ± 20.4 mL/min and 66.9 ± 21.4 mL/min at month 6) and the rate of treatment failure was low (1.9% of which 1.7% biopsy-proven acute rejection within 6 months of converting to study medication, no episodes of graft loss). EC-MPS was well tolerated with only mild to moderate severity adverse-events (6.5% hematological, 23.5% GI), leading to dose reductions (6.3%) or drug interruption (3.4%). The results of this large multi-center study provided further proof of the safety and maintained effi cacy of EC-MPS compared to MMF in maintenance immunosuppression for renal transplant recipients.
Another pooled analysis of three myPROMS sub-studies (US01, DE01, FR01 substudies performed in USA, Germany and France, respectively) evaluated the effi cacy and tolerability of EC-MPS de novo in renal transplantation. All patients received steroids and basiliximab induction and were randomized in standard or low-dose CsA, and early (day 0) or delayed (day 6 after transplantation) CsA introduction treatment groups. 74 There was 25.9% treatment failure reported at 12 months after transplantation (22.1% biopsy-proven acute rejection, 3.1% graft loss) and renal function was stable (median calculated creatinine clearance 62.9 mL/min). There was no signifi cant difference between CsA treatment groups at month 6 and 12 in terms of biopsyproven acute rejection, graft and patient survival and graft function. High EC-MPS dosing was sustained throughout the study period (Ͼ90% recommended dose) and dose modifi cations due to EC-MPS-related adverse-events or infections were infrequent. Similarly, we have analysed a sub-group of 140 de novo kidney-transplant recipients from 11 centers in Europe, treated with EC-MPS and CsA microemulsion with or without steroids. 75 The incidence of treatment failure, 
MPA exposure and therapeutic drug monitoring
Based on the results of pivotal large prospective randomized trials, MMF was approved for the prevention of acute rejection in renal transplantation in combination with CsA and steroids. [22] [23] [24] But unlike other maintenance immunosuppressive drugs such as CNI or mTOR inhibitors, MMF was introduced into routine clinical practice on a fi xed-dose recommendation (2 or 3 g/day). As discussed, these standard-dose regimens have overall proven to be effi cient in preventing early acute rejection as well as late rejection and graft failure. However, it has been shown that for an identical oral dose of MMF, there is an intra-and inter-patient variability of the pharmacokinetics of MPA. Indeed, factors such as renal function, serum albumin and bilirubine, concurrent medication (in particular CsA), altered GI absorption, and host genetics may infl uence MPA exposure. 76, 77 Thus, fi xed-dose MMF therapy may lead to under-or over-immunosuppression leading to increased risk of acute rejection or drug toxicity, respectively. Clinical studies have reported a signifi cant correlation between incidence of acute rejection and MPA plasma concentrations. [78] [79] [80] Therapeutic drug monitoring of the active metabolite MPA pharmacokinetic parameters would allow optimizing the effi cacy and safety of immunosuppression and a more individualized-based treatment. 81 The most reliable measure of MPA exposure is the 12-hour area under the plasma concentration-time curve (AUC 0-12 ). The measurement however implies blood samples drawn over a 12-hour time interval and is not feasible in routine clinical practice. Predose measurement (trough levels) of MPA is an alternative to AUC, but is less accurate due to greater within-patient variability. Simplifi ed limited sampling AUC strategies have been proposed and evaluated in renal transplant patients at various time-points after transplantation. 80, [82] [83] [84] These strategies have been shown to accurately estimate individual MPA AUC using a limited number of blood samples and are now being used for MPA dose-adaptation in concentration-controlled studies in clinical practice. Moreover, as the biological activity of MPA may be more relevant than its pharmacokinetic parameters in correlating with clinical outcome, an assay based on the measurement of IMP deshydrogenase activity in peripheral blood mononuclear cells has been reported. 85 The benefi t of TDM in renal transplantation outcome was evaluated in a 12-month prospective French trial (APOMYGRE), with 137 transplant recipients randomized to receive either concentration-controlled or fi xed-dose MMF, together with basiliximab induction, CSA and steroids. 80 The incidence of treatment failure (a composite of death, graft loss, acute biopsy-proven rejection, MMF discontinuation) was signifi cantly lower in the concentration-controlled group (29.2% vs 47.7%), which interestingly received a higher MMF dose in the fi rst 3 months after transplantation. Compared to MMF, equimolar doses of EC-MPS result in similar MPA exposure, but there are less data available on TDM for EC-MPS and the correlation with clinical outcome. 86 Because of technical diffi culties, costs and concerns about the optimal methodology to use, controversies exist whether TDM of the active metabolite MPA should be applied to all renal transplant recipients. 87, 88 Based on the association between clinical events and MPA exposure and the known pharmacokinetic variability, TDM has been recommended in defi ned clinical settings to establish adequate individualized MPA levels. 89 In the fi rst weeks after transplantation, patients with concurrent CsA administration were found to have MPA AUC below target levels with MMF 2 g/day. CSA, as opposed to TAC, inhibits the enterohepatic recirculation of MPA, resulting in lower MPA concentrations and potential under-exposure. Thus, TDM would be useful in the immediate post transplantation period, in high immunological risk patients, when reducing or withdrawing CSA or switching from/to another immunosuppressant such as TAC or mTOR inhibitors. It would also allow to monitor the overall degree of immunosuppression during a clinical event such as rejection or the occurrence of severe side-effects.
Conclusion and perspectives
In order to improve allograft and patient survival, the main objective of current immunosuppressive regimens is to prevent acute rejection episodes which may negatively impact on short and long-term outcomes, while limiting drug-related toxicity including CAN. Because of the good safety profi le and great effi cacy of MMF demonstrated in large randomized pivotal trials, most transplantation programs now routinely use MPA formulations rather than AZA in their immunosuppressive maintenance regimens.
The use of MPA formulations, both MMF and EC-MPS, can however be limited by their side-effects (mainly GI and hematological) especially in advanced renal failure, as well as higher costs compared to AZA. In this regard, it is worth noting that the early prospective randomized trials that have lead to "standard" CsA-MMF-prednisone triple therapy had used an old formulation of CsA. A recent multi-center prospective randomized cadaveric renal transplantation study (Mycophenolate Steroids Sparing, MYSS trial), comparing the effi cacy of MMF (2 g/day) to AZA (75-100 mg/day) in combination with the CsA-microemulsion formulation (Neoral) and steroids showed no clear advantage of MMF over AZA in preventing early (Ͻ6 months after transplantation) as well as late (Ͼ6 months after transplantation) occurring acute rejection. 90 In the extension of MYSS, the follow-up study, graft function, incidence of late rejections and adverse events, graft and patient survival were comparable among both treatment groups at 5-years follow-up. The authors concluded that in kidney transplantation, short as well as long-term effi cacy profi les of MMF and AZA therapy in combination with CsA-microemulsion were similar. 91 They also pointed out that MMF treatment was about 15 times more expensive.
Overall, the addition and type of induction therapy, the type and dosage of CNI versus other anti-proliferative agents such as mTOR-inhibitors in maintenance immunosuppressive regimens together with MMF may impact differently on the rate of acute allograft rejection and graft survival. Further large prospective long-term studies are needed to better determine the combination therapy that would provide optimal graft and patient outcome. In addition, treatment based on TDM would provide individualized immunosuppression and may help optimize the effi cacytoxicity profi le of immunosuppressive drugs and further improve clinical outcome. Cost-effectiveness should also be an issue in the choice of medication as well as the type of monitoring of standard immunosuppressive regimens for renal transplant recipients.
